SCHEMBL905614

SCHEMBL905614

COc1ccc(C2CC(=O)c3c(cc(O)c(OC)c3O)O2)cc1OC

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.73
RAB9A P51151 2/20 0.73
TAS2R31 P59538 2/20 0.69
TP53 P04637 2/20 0.62
CYP3A4 P08684 2/20 0.62
CYP19A1 P11511 2/20 0.62
XDH P47989 2/20 0.62
CYP1A1 P04798 2/20 0.62
CYP1A2 P05177 2/20 0.62
CYP1B1 Q16678 2/20 0.62
POLB P06746 2/20 0.62
MAPT P10636 2/20 0.62
ALDH1A1 P00352 2/20 0.62
ATM Q13315 2/20 0.62
HPGD P15428 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
PKM P14618 1/20 0.62
CA12 O43570 1/20 0.62
KDM1A O60341 1/20 0.62
CYP2D6 P10635 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30716844 0.88 NPC1 (0.77) NPC1RAB9ATAS2R31TP53CYP3A4
SCHEMBL27775449 0.87 NPC1 (0.82) NPC1RAB9ATAS2R31TP53CYP3A4
SCHEMBL382207 0.86 TAS2R31 (0.79) NPC1RAB9ATAS2R31TP53CYP3A4
Dihydrooroxylin A SCHEMBL31682921 0.85 NPC1 (1.00) NPC1RAB9ATAS2R31CYP3A4CYP19A1
Dihydrooroxylin A SCHEMBL12067042 0.85 NPC1 (1.00) NPC1RAB9ATAS2R31CYP3A4CYP19A1
SCHEMBL31028356 0.84 CYP19A1 (0.87) NPC1RAB9ATAS2R31TP53CYP3A4
SCHEMBL7605704 0.84 TAS2R31 (0.65) NPC1RAB9ATAS2R31TP53CYP3A4
SCHEMBL28589889 0.83 TAS2R31 (0.64) NPC1RAB9ATAS2R31TP53CYP3A4
SCHEMBL30865912 0.83 TAS2R31 (0.64) NPC1RAB9ATAS2R31TP53CYP3A4
SCHEMBL14421486 0.83 TAS2R31 (0.57) NPC1RAB9ATAS2R31TP53CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2277595-A2 Compounds for immunopotentiation Novartis Vaccines and Diagnostics, Inc. (US) 2011-01-26 EP disclosed
US-20100226931-A1 Compounds for immunopotentiation NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2010-09-09 US disclosed
EP-1765313-A2 COMPOUNDS FOR IMMUNOPOTENTIATION Novartis Vaccines and Diagnostics, Inc. (US) 2007-03-28 EP disclosed
WO-2006002422-A9 COMPOUNDS FOR IMMUNOPOTENTIATION CHIRON CORP (US) 2006-09-21 WO disclosed
WO-2006002422-A2 COMPOUNDS FOR IMMUNOPOTENTIATION NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) 2006-01-05 WO disclosed
US-6025387-A Gastroprotective flavone/flavanone compounds with therapeutic effect on inflammatory bowel disease DONG A PHARMACEUTICAL CO., LTD. (KR) 2000-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100226931-A1 Compounds for immunopotentiation LY96, ICOS, PDCD1 NPC1 3691/4885RAB9A 1608/4885TAS2R31 2594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.